explore -WSS

explore

author：entertainment 2025-10-01 18:33:00 - browse：17

IQVIA signage. -- health tech coverage from STAT — Adobe

The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： NEJM study link tiny plastics in blood vessels to heart problems

entertainment

WSS

The problem with charging patients to message their doctors

President Biden's budget: Here's what you might have missed

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

How to bring more disabled researchers into academia

John Green on his newest strategy for fighting tuberculosis

How to save health care price transparency rules

leisure time

explore

explore

Medicare proposal to cover medical devices draws a mixed reaction

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Hepatitis C has a cure — but many Americans still lack access to it

Amylyx ALS drug failure raises questions and concerns

23andMe had bad news about my health. I wish a person had delivered it

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Anesthesiologist group: stop taking Ozempic before surgery

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

Continuity nursing helped my family in our darkest PICU moments

A deep dive into Applied Therapeutics’ data, and questions on Cassava

explore

First U.S. drug developed to treat liver disease MASH is approved

Novo Nordisk obesity pill bests Wegovy in early trial

How many hemophilia patients actually want gene therapy?

Change Healthcare cyberattack prompts Medicare loan program

Why scientists need input from humanists on sensitive research

Change Healthcare cyberattack prompts Medicare loan program

entertainment

hotspot

Wikipedia

explore